Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: Safety, efficacy and quality of life

Veterinary Dermatology

Volumn 26, Issue 3, 2015, Pages 171-e35

  Cosgrove, Sallie B ^a   Cleaver, Dawn M ^a   King, Vickie L ^a   Gilmer, Amy R ^a   Daniels, Anne E ^a   Wren, Jody A ^a   Stegemann, Michael R ^b  

^a ZOETIS   (United States)

^b Zoetis Veterinary Medicine Research and Development   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

DERMATOLOGICAL AGENT; OCLACITINIB; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL; CLINICAL TRIAL; COMPASSIONATE USE; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; DOG; DOG DISEASES; DRUG ADMINISTRATION; FEMALE; MALE; PRURITUS; QUALITY OF LIFE; TREATMENT OUTCOME; VETERINARY; VISUAL ANALOG SCALE;

ANIMALS; COMPASSIONATE USE TRIALS; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; PRURITUS; PYRIMIDINES; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 84929273770     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/vde.12194     Document Type: Article

References (25)

1. ® product label. Available at: https://www.zoetisus.com/bmst-minisite-apoquel/documents/finalapoquel_pi_8_5x11.pdf?utm_source=Prescribing&utm_medium=click&utm_campaign=Apoquelztssite. Accessed Jan 6, 2015.
2. US Food and Drug Administration website. Apoquel FOI. Available at: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM363901.pdf. Accessed Dec 09, 2014.
3. Veterinary Drugs Directorate of Health Canada website. Apoquel. Available at: http://webprod5.hc-sc.gc.ca/noc-ac/index-eng.jsp. Accessed Jan 6, 2015. [Note: Under Brand/Product Name, type Apoquel and you will have a list of all strengths approved and the date of NOC.]
4. European Medicines Agency website. Apoquel. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/veterinary/medicines/002688/vet_med_000280.jsp&mid=WC0b01ac058001fa1. Accessed Oct 9, 2013.
5. Cosgrove SB, Wren JA, Cleaver DM et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24: 479-e114.
6. ®) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24: 587-597, e141-e142.
7. ®) for the control of atopic dermatitis in client-owned dogs using visual analog scale and CADESI Scores. Vet Dermatol 2013; 24:381 (abstract).
8. Cosgrove SB, Wren JA, King VL et al. A multicentre clinical trial to evaluate efficacy and field safety of oclacitinib. Vet Dermatol 2012; 23: 38 (abstract).
9. US Food and Drug Administration website. Access to investigational drugs outside of a clinical trial (expanded access). Available at: http://www.fda.gov/forpatients/other/expandedaccess/default.htm. Accessed Jan 6, 2015.
10. Olivry T, Foster AP, Mueller RS et al. Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Vet Dermatol 2010; 21: 4-22.
11. Olivry T, Mueller RS. The International Task Force on Canine Atopic Dermatitis. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003; 14: 121-146.
12. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-287.
13. Good Clinical Practice website. International co-operation on harmonisation of technical requirements for registration of veterinary medicinal products (VICH). Available at: http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM052417.pdf. Accessed Jan 6, 2015.
14. Noli C, Manafo G, Galzerano M. Quality of life of dogs with skin diseases and their owners. Part 1: development and validation of a questionnaire. Vet Dermatol 2011; 22: 335-343.
15. Noli C, Colombo S, Cornegliani L et al. Quality of life of dogs with skin disease and of their owners. Part 2: administration of a questionnaire in various skin diseases and correlation to efficacy of therapy. Vet Dermatol 2011; 22: 344-351.
16. Favrot C, Linek M, Mueller R et al. Development of a questionnaire to assess the impact of atopic dermatitis on health-related quality of life of affected dogs and their owners. Vet Dermatol 2010; 21: 64-70.
17. Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. Vet Dermatol 2010; 21: 456-462.
18. International co-operation on harmonisation of technical requirements for registration of veterinary medicinal products (VICH). Pharmacovigilance of veterinary medicinal products webpage: "Management of adverse event reports (AERs). Available at pharmacovigilance of veterinary medicinal products: management of adverse event reports (AERs) website. Available at: http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM052657.pdf. Accessed Jan 6, 2015.
19. Rybnicek J, Lau-Gillard PJ, Harvey R et al. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol 2009; 20: 115-122.
20. Lulich JP, Osborne CA, Barteges JW et al. The urinary system. In: Ettinger and Feldman's Textbook of Veterinary Internal Medicine 5th edition. Philadelphia: W.B. Saunders Co. 2000; 1748.
21. Hahn KA, Oglivie G, Rusk T et al. Mastitinib is safe and effective for the treatment if canine mast cell tumors. J Vet Intern Med 2008; 22: 1301-1309.
22. Berrocal A, Vos JH, Ingh TSGAM et al. Canine perineal tumours. J Vet Med Series A 1989; 36: 739-749.
23. Goldschmidt MH, Shofer FS. Anal sac gland tumors. In Skin Tumors of the Dog and Cat. Oxford, UK: Pergamon Press 1992; 103-108.
24. th edition. Philadelphia: W.B. Saunders Co. 2007; 68-76.
25. Bronson RT. Variation in age at death of dogs of different sexes and breeds. Am J Vet Res 1982; 43: 2057-2059.